Abstract
G protein-coupled receptors (GPCRs), especially the class A, are the most heavily investigated drug targets in the pharmaceutical industry. Tremendous efforts have been made by both industry and academia to understand the molecular structure and function of this large family of transmembrane proteins. Our understanding in GPCR activation has evolved from the classical inactive-active two-state model to a complex view of GPCR conformational ensemble associated with multiple interacting partners such as ligands, allosteric modulators, ions and downstream signaling proteins. New drug targets and ligand design strategies are unveiled. Meanwhile, breakthroughs in X-ray crystallography have resulted in high-resolution structures of over 30 GPCRs, providing structural basis for drug design and functional studies. These enabled wide applications of computational approaches in GPCR research that have led to several groundbreaking studies in the last few years. While a large fraction of human GPCRs has yet to be crystallized, homology modeling plays a pivotal role in the simulation of these GPCRs. Here, we review the recent updates on class A GPCR structure and function, with a focus on the applications and perspectives of molecular modeling in GPCR ligand design.
Keywords: GPCR, ligand design, allosteric modulation, ligand bias, homology modeling, molecular dynamics.
Current Pharmaceutical Design
Title:Class A GPCRs: Structure, Function, Modeling and Structure-based Ligand Design
Volume: 23 Issue: 29
Author(s): Xiaojing Cong*, Jeremie Topin and Jerome Golebiowski*
Affiliation:
- Institute of Chemistry - Nice, UMR 7272 CNRS - University Nice - Sophia Antipolis, 06108 Nice cedex 2,France
- Institute of Chemistry - Nice, UMR 7272 CNRS - University Nice - Sophia Antipolis, 06108 Nice cedex 2,France
Keywords: GPCR, ligand design, allosteric modulation, ligand bias, homology modeling, molecular dynamics.
Abstract: G protein-coupled receptors (GPCRs), especially the class A, are the most heavily investigated drug targets in the pharmaceutical industry. Tremendous efforts have been made by both industry and academia to understand the molecular structure and function of this large family of transmembrane proteins. Our understanding in GPCR activation has evolved from the classical inactive-active two-state model to a complex view of GPCR conformational ensemble associated with multiple interacting partners such as ligands, allosteric modulators, ions and downstream signaling proteins. New drug targets and ligand design strategies are unveiled. Meanwhile, breakthroughs in X-ray crystallography have resulted in high-resolution structures of over 30 GPCRs, providing structural basis for drug design and functional studies. These enabled wide applications of computational approaches in GPCR research that have led to several groundbreaking studies in the last few years. While a large fraction of human GPCRs has yet to be crystallized, homology modeling plays a pivotal role in the simulation of these GPCRs. Here, we review the recent updates on class A GPCR structure and function, with a focus on the applications and perspectives of molecular modeling in GPCR ligand design.
Export Options
About this article
Cite this article as:
Cong Xiaojing*, Topin Jeremie and Golebiowski Jerome *, Class A GPCRs: Structure, Function, Modeling and Structure-based Ligand Design, Current Pharmaceutical Design 2017; 23 (29) . https://dx.doi.org/10.2174/1381612823666170710151255
DOI https://dx.doi.org/10.2174/1381612823666170710151255 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc., has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-Based Biomarkers in Large-Scale Screening for Neurodegenerative Diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Diabetes Mellitus: Advances in Diagnosis and Treatment driving by Precision Medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CD93: Recent Advances and Implications in Disease
Current Drug Targets Unraveling the Concealed Transcriptomic Landscape of PTEN in Human Malignancies
Current Genomics Study about How A Sample of Portuguese People Perceive the Health Benefits of Dietary Fibre
Current Nutrition & Food Science The Association of Chemotherapy and Radiotherapy in Squamous Cell Carcinoma of Anal Canal
Current Drug Therapy Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases
Current Medicinal Chemistry A Small-molecule Inhibitor, 5'-O-Tritylthymidine, Targets FAK and Mdm-2 Interaction, and Blocks Breast and Colon Tumorigenesis in vivo
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA Cardiovascular Risk Factors: Does Sex Matter?
Current Vascular Pharmacology Drug Target Identification for Neuronal Apoptosis Through a Genome Scale Screening
Current Medicinal Chemistry Looking Beyond Inhibition of VEGF/mTOR: Emerging Targets for Renal Cell Carcinoma Drug Development
Current Clinical Pharmacology Apolipoprotein B Antisense Inhibition -Update on Mipomersen
Current Pharmaceutical Design Antipsychotic Drugs and Risk of Developing Venous Thromboembolism and Pulmonary Embolism: A Systematic Review and Meta-Analysis
Current Vascular Pharmacology In Silico Protein-Protein Interactions: Avoiding Data and Method Biases Over Sensitivity and Specificity
Current Protein & Peptide Science Uncoupling Proteins: Role in Insulin Resistance and Insulin Insufficiency
Current Diabetes Reviews Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives
Anti-Cancer Agents in Medicinal Chemistry Serial Analysis of Gene Expression in Eukaryotic Pathogens
Infectious Disorders - Drug Targets Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Releasing of Herpes Simplex Virus Carrying NGF in Subarachnoid Space Promotes the Functional Repair in Spinal Cord Injured Rats
Current Gene Therapy